论文部分内容阅读
华法林是目前临床上应用最广泛的口服抗凝药,其治疗安全范围窄,剂量个体差异大,临床应用中容易出现抗凝不当所致的并发症。近3年来,随着药物基因组学的快速发展,发现细胞色素P450酶4F2(CYP4F2)基因多态性(rs2108622)与华法林个体剂量差异相关。本文综述了近3年来在不同人种中进行的有关CYP4F2*3(rs2108622)与华法林的维持剂量关系的研究。大多数研究发现CYP4F2基因多态性与华法林维持剂量存在相关性,其中突变的T等位基因与华法林高剂量相关;CYP4F2*3可以解释1%～10%华法林剂量个体差异。
Warfarin is currently the most widely used clinical oral anticoagulant, its narrow range of safety of treatment, the dose of individual differences, clinical application prone to complications caused by improper anticoagulation. In the recent 3 years, with the rapid development of pharmacogenomics, it has been found that the CYP4F2 gene polymorphism (rs2108622) is related to the difference of individual dose of warfarin. This review summarizes studies on the relationship between CYP4F2 * 3 (rs2108622) and warfarin maintenance doses in different ethnic groups over the past three years. Most studies found that CYP4F2 gene polymorphism and warfarin maintenance dose there is a correlation, including mutations in the T allele and warfarin high dose CYP4F2 * 3 can explain 1% to 10% of warfarin dose individual differences .